Anti-hypertensive and renoprotective effects of berberine in spontaneously hypertensive rats

Clinical and Experimental Hypertension

Volumn 37, Issue 4, 2015, Pages 332-339

  Guo, Zhentao ^a   Sun, Hongri ^b   Zhang, Huamin ^b   Zhang, Yanfeng ^b  

^a WEIFANG MEDICAL UNIVERSITY   (China)

^b Changyi People's Hospital   (China)

Author keywords

Aldosterone; Angiotensin II; Berberine; Blood pressure; IL 17; IL 23; IL 6; Renal damage; SHR

Indexed keywords

ALBUMIN; ALDOSTERONE; ANGIOTENSIN II; BERBERINE; COLLAGEN TYPE 3; COLLAGEN TYPE 4; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; KIDNEY INJURY MOLECULE 1; OSTEOPONTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; HYPERTENSION; KIDNEY HOMOGENATE; KIDNEY INJURY; MALE; NONHUMAN; RAT; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; ANIMAL; BLOOD PRESSURE; DISEASE MODEL; DRUG EFFECTS; GLOMERULUS FILTRATION RATE; KIDNEY; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR KYOTO RAT;

ANIMALS; BERBERINE; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; GLOMERULAR FILTRATION RATE; HYPERTENSION; KIDNEY; MALE; RATS; RATS, INBRED SHR; RATS, INBRED WKY;

EID: 84936951000     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2014.972560     Document Type: Article

References (28)

1. Shin SM, Shim WJ, Park SM. Early changes of left ventricular function in young adults with never-treated hypertension and no left ventricular hypertrophy: relationships to ambulatory blood pressure monitoring. Clin Exp Hypertens 2014;30:1-7.
2. Hall JE. The kidney, hypertension, and obesity. Hypertension 2003; 41:625-33.
3. Whelton PK, Klag MJ. Hypertension as a risk factor for renal disease. Review of clinical and epidemiological evidence. Hypertension 1989;13:I19-27.
4. Carlsson AC, Ruge T, Sundström J, et al. Association between circulating endostatin, hypertension duration, and hypertensive target-organ damage. Hypertension 2013;62:1146-51.
5. Santos PC, Krieger JE, Pereira AC. Renin-angiotensin system, hypertension, and chronic kidney disease: pharmacogenetic implications. J Pharmacol Sci 2012;120:77-88.
6. Kita T, Yokota N, Ichiki Y, et al. Three-year safety and effectiveness of fixed-dose losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension under clinical setting (PALM-1 Extension Study). Clin Exp Hypertens 2012;34:498-503.
7. Trott DW, Harrison DG. The immune system in hypertension. Adv Physiol Educ 2014;38:20-4.
8. Schiffrin EL. Immune mechanisms in hypertension and vascular injury. Clin Sci (Lond) 2014;126:267-74.
9. Miguel-Carrasco JL, Zambrano S, Blanca AJ, et al. Captopril reduces cardiac inflammatory markers in spontaneously hypertensive rats by inactivation of NF-kB. J Inflamm (Lond) 2010;7:21. doi:10.1186/1476-9255-7-21.
10. Lukic L, Lalic NM, Rajkovic N, et al. Hypertension in obese type 2 diabetes patients is associated with increases in insulin resistance and IL-6 cytokine levels: potential targets for an efficient preventive intervention. Int J Environ Res Public Health 2014;11:3586-98.
11. Kang YS. Obesity associated hypertension: new Insights into mechanism. Electrolyte Blood Press 2013;11:46-52.
12. Harrison DG, Marvar PJ, Titze JM. Vascular inflammatory cells in hypertension. Front Physiol 2012;3:128. doi:10.3389/fphys.2012.00128.
13. Trott DW, Harrison DG. The immune system in hypertension. Adv Physiol Educ 2014;38:20-4.
14. Chen C, Yu Z, Li Y, et al. Effects of berberine in the gastrointestinal tract - a review of actions and therapeutic implications. Am J Chin Med 2014;42:1053-70.
15. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 2008;57:712-17.
16. Meng S, Wang LS, Huang ZQ, et al. Berberine ameliorates inflammation in patients with acute coronary syndrome following percutaneous coronary intervention. Clin Exp Pharmacol Physiol 2012;39:406-11.
17. Li Z, Geng YN, Jiang JD, Kong WJ. Antioxidant and antiinflammatory activities of berberine in the treatment of diabetes mellitus. Evid Based Complement Alternat Med 2014;2014: 289264.
18. Li MH, Zhang YJ, Yu YH, et al. Berberine improves pressure overload-induced cardiac hypertrophy and dysfunction through enhanced autophagy. Eur J Pharmacol 2014;728:67-76.
19. Kang DG1, Sohn EJ, Kwon EK, et al. Effects of berberine on angiotensin-converting enzyme and NO/cGMP system in vessels. Vascul Pharmacol 2002;39:281-6.
20. Pérez-Rubio KG, González-Ortiz M, Martínez-Abundis E, et al. Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord 2013; 11:366-9.
21. Xie HH, Shen FM, Miao CY, Su DF. Blood pressure, baroreflex sensitivity, and end organ damage in hybrid offspring of spontaneously hypertensive rats and Sprague-Dawley rats. Acta Pharmacol Sin 2005;26:1049-56.
22. Regner KR, Harmon AC, Williams JM, et al. Increased susceptibility to kidney injury by transfer of genomic segment from SHR onto Dahl S genetic background. Physiol Genomics 2012;44: 629-37.
23. Mihailovic-Stanojevic N1, Jovovic D, Miloradovic Z, et al. Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan. Nephrol Dial Transplant 2009; 24:1142-50.
24. Wu D, Wen W, Qi CL, et al. Ameliorative effect of berberine on renal damage in rats with diabetes induced by high-fat diet and streptozotocin. Phytomedicine 2012;19:712-18.
25. Zhang Q1, Davis KJ, Hoffmann D, et al. Urinary biomarkers track the progression of nephropathy in hypertensive and obese rats. Biomark Med 2014;8:85-94.
26. Li HB, Cai Y, Qi CL, Lv JH. Effects and mechanism of berberine on the hypertensive renal injury rats induced by enriched high fatsalt-fructose diet. Zhong Yao Cai 2011;34:412-15.
27. Nguyen H, Chiasson VL, Chatterjee P, et al. Interleukin-17 causes Rho-kinase-mediated endothelial dysfunction and hypertension. Cardiovasc Res 2013;97:696-704.
28. Krebs CF, Lange S, Niemann G, et al. Deficiency of the interleukin 17/23 axis accelerates renal injury in mice with deoxycorticosterone acetate +angiotensin ii-induced hypertension. Hypertension 2014;63:565-71.